Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC1-targeted CAR-T cells (Zhujiang Hospital)
- Development stage
- Unknown
- Lead developer
- Southern Medical University Zhujiang Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an experimental chimeric antigen receptor T-cell (CAR-T) therapy developed by Zhujiang Hospital of Southern Medical University for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy involves genetically engineering a patient's own T cells to express a chimeric antigen receptor that specifically recognizes MUC1 (Mucin 1), a glycoprotein often aberrantly expressed on the surface of AML cells. By targeting MUC1, these CAR-T cells are designed to selectively identify and eliminate leukemic cells while sparing normal tissues. This therapy is being evaluated as part of a broader clinical strategy (NCT03473457) that explores various antigen targets, including CD33, CD38, and CD123, to address the heterogeneity and antigen escape common in AML.
- Other names
- anti-MUC1 CAR-Tanti-MUC-1 CAR-Tanti-MUC 1 CAR-TMUC1-specific CAR-T cellsMUC-1-specific CAR-T cellsMUC 1-specific CAR-T cells
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on MUC1-targeted CAR-T cells (Zhujiang Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC1-targeted CAR-T cells (Zhujiang Hospital).